Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H11O6S.Na |
Molecular Weight | 330.288 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].COC1=CC(O)=C(C=C1S([O-])(=O)=O)C(=O)C2=CC=CC=C2
InChI
InChIKey=KJCLYACXIWMFCC-UHFFFAOYSA-M
InChI=1S/C14H12O6S.Na/c1-20-12-8-11(15)10(7-13(12)21(17,18)19)14(16)9-5-3-2-4-6-9;/h2-8,15H,1H3,(H,17,18,19);/q;+1/p-1
Molecular Formula | C14H11O6S |
Molecular Weight | 307.299 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm330694.htmCurator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/?term=11407932; https://www.ncbi.nlm.nih.gov/pubmed/1729569; https://books.google.com/books?id=AmqJDAAAQBAJ&pg=PA209&lpg=PA209&dq=SULISOBENZONE+was+first+developed+by&source=bl&ots=RZpF_2Yj4K&sig=Cjei8l5DytTpZyrMSIYfMF3grtE&hl=en&sa=X&ved=0ahUKEwiKrPjK_KHPAhWFWT4KHXG4A6UQ6AEIOTAF#v=onepage&q=SULISOBENZONE%20was%20first%20developed%20by&f=false
Sources: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/ucm330694.htm
Curator's Comment: Description was created using several sources including:
https://www.ncbi.nlm.nih.gov/pubmed/?term=11407932; https://www.ncbi.nlm.nih.gov/pubmed/1729569; https://books.google.com/books?id=AmqJDAAAQBAJ&pg=PA209&lpg=PA209&dq=SULISOBENZONE+was+first+developed+by&source=bl&ots=RZpF_2Yj4K&sig=Cjei8l5DytTpZyrMSIYfMF3grtE&hl=en&sa=X&ved=0ahUKEwiKrPjK_KHPAhWFWT4KHXG4A6UQ6AEIOTAF#v=onepage&q=SULISOBENZONE%20was%20first%20developed%20by&f=false
Sulisobenzone (benzophenone-4) is an ingredient for use in sunscreens which protects the skin from damage by UVB and short-wave UVA ultraviolet light. The Food and Drug Administration (FDA) has approved the use of Benzophenone-4 as safe and effective, over-the-counter (OTC) sunscreen ingredient. Sulisobenzone is a subject to the FDA 2011 sunscreen final rule: it can be marketed without approved drug applications (without NDAs or ANDAs), must bear the statement of identity “sunscreen" and contain the information about SPF test. However it is said to be widely used in cosmetic products not labeled as sunscreens such as creams, moisturizers, shampoos and other hair care products, nail polish, lipsticks and lip balms. Sulisobenzone may cause contact dermatitis when used in cosmetics and toiletries. Benzophenone 4 is tested as 10%. It was reported that 10% sulisobenzone enhance skin penetration of the moderately lipophilic herbicide 2,4-D.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 μg/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32088184/ |
0.1 mg single, topical dose: 0.1 mg route of administration: Topical experiment type: SINGLE co-administered: |
SULISOBENZONE unknown | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32088184/ |
0.1 mg single, topical dose: 0.1 mg route of administration: Topical experiment type: SINGLE co-administered: |
SULISOBENZONE unknown | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32088184/ |
0.1 mg single, topical dose: 0.1 mg route of administration: Topical experiment type: SINGLE co-administered: |
SULISOBENZONE unknown | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Contact and photocontact allergy to ketoprofen. The Belgian experience. | 2004 Apr |
|
Active ingredients in sunscreens act as topical penetration enhancers for the herbicide 2,4-dichlorophenoxyacetic acid. | 2004 Mar 15 |
|
A reversed-phase ion-interaction chromatographic method for in-vitro estimation of the percutaneous absorption of water-soluble UV filters. | 2008 Jun |
|
Solid-phase extraction followed by liquid chromatography-tandem mass spectrometry for the determination of hydroxylated benzophenone UV absorbers in environmental water samples. | 2009 Nov 10 |
|
Development of a fully automated sequential injection solid-phase extraction procedure coupled to liquid chromatography to determine free 2-hydroxy-4-methoxybenzophenone and 2-hydroxy-4-methoxybenzophenone-5-sulphonic acid in human urine. | 2010 Apr 7 |
|
The UV-absorber benzophenone-4 alters transcripts of genes involved in hormonal pathways in zebrafish (Danio rerio) eleuthero-embryos and adult males. | 2011 Jan 15 |
Sample Use Guides
Apply sunscreen that contains Avobenzone 3.00% Octinoxate 7.49% Octocrylene 2.00% Sulisobenzone 1.50% liberally 15 minutes before sun exposure. Reapply at least every 2 hours. Children under 6 months of age: ask a doctor.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=12147043
After 1 hr incubation with five test concentrations of each chemical compound, epidermis was then exposed or not to UVA at a non-cytotoxic dose (50 J/sq cm). 18 hr after UVA exposure, cellular damage was evaluated measuring cytotoxicity by MTT conversion test.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:00:10 UTC 2023
by
admin
on
Fri Dec 15 16:00:10 UTC 2023
|
Record UNII |
853Z42ZYAS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002279
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY | |||
|
853Z42ZYAS
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY | |||
|
6628-37-1
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY | |||
|
1428833
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY | RxNorm | ||
|
23674885
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY | |||
|
853Z42ZYAS
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY | |||
|
DTXSID40216481
Created by
admin on Fri Dec 15 16:00:10 UTC 2023 , Edited by admin on Fri Dec 15 16:00:10 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |